3 completed, 1 unknown. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Unknown 1 |
Follow etesevimab: new trials by email Literature Review of etesevimab trials Research Report on etesevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19 JS026/placebo, JS016/placebo - COVID-19 | Phase 1 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 48 | 2021-12-16 | 2023-08-01 |
| A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 LY3832479, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 18 | 2020-11-02 | 2021-12-06 |
| A Study of LY3832479 (LY-CoV016) in Healthy Participants LY3832479, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 26 | 2020-06-19 | 2021-12-06 |
| Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects JS016 (anti-SARS-CoV-2 monoclonal antibody) - COVID-19; and High Infection Risk of SARS-CoV-2 | Phase 1 | Unknown | Shanghai Junshi Bioscience Co., Ltd. | 40 | 2020-06-05 | 2020-06-22 |
COVID-19 (2)
Eli Lilly and Company (2) · Shanghai Junshi Bioscience Co., Ltd. (2)
China (2) · United States (2)